Cabergoline Improves Metabolic Status in Hyperprolactinemia

A single-center, observational study suggests that 6 months of treatment with the dopamine agonist cabergoline improves cardiometabolic measures in patients with a prolactinoma and hyperprolactinemia.
First Look

source https://www.medscape.com/viewarticle/974577?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?